# Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

> **NCT03680092** · PHASE2 · COMPLETED · sponsor: **Dimitrios Tzachanis, MD PhD** · enrollment: 43 (actual)

## Conditions studied

- GVHD
- Hematologic Neoplasms

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** abatacept
- **DRUG:** Methotrexate
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT03680092
- **Lead sponsor:** Dimitrios Tzachanis, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-26
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03680092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03680092, "Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03680092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*